ArticleSurgery today2011

Predictors of the efficacy of FOLFIRI plus bevacizumab as second-line treatment in metastatic colorectal cancer patients.

Mitsukuni Suenaga et al.PubMed ↗Publisher ↗

No numbers read from the abstract.